Systemic Inhibition of PTPN22 Augments Anticancer Immunity

0
97
In mice, lack of PTPN22 augmented antitumor activity with greater infiltration and activation of macrophages, natural killer (NK) cells, and T cells.
[Journal of Clinical Investigation]
Ho, W. J., Croessmann, S., Lin, J., Phyo, Z. H., Charmsaz, S., Danilova, L., Mohan, A. A., Gross, N. E., Chen, F., Dong, J., Aggarwal, D., Bai, Y., Wang, J., He, J., Leatherman, J. M., Yarchoan, M., Armstrong, T. D., Zaidi, N., Fertig, E. J., … Jaffee, E. M. (2021). Systemic inhibition of PTPN22 augments anticancer immunity. The Journal of Clinical Investigation. https://doi.org/10.1172/JCI146950 Cite
AbstractGraphical Abstract